Search Our Trials
We are currently enrolling patients in the Clinical Trials listed below. New trials open regularly, and availability is subject to change. Search using key terms to find trials for which you may be eligible.
We are here to answer your questions and guide you through this process with HOPE and compassion for your unique journey.
- C: (972) 566-3082 E: Referral@MaryCrowley.org
Search Results
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
JIT-MCLA-129-CL01
MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody
Immunotherapy
EGFR, MET
Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC)
No
JIT-MCLA-128-CL01
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
Molecular Targeted Therapy
HER2, HER3
Lung Cancer (NSCLC), Pancreatic Cancer
No
JIT-F8394-201
n/a
Molecular Targeted Therapy
BRAF
Central Nervous System Tumor, GBM (Glioblastoma)
No
JIT-ENV-ONC-101
ENV- 101, a potent Hedgehog (Hh) pathway inhibitor
n/a
PTCH1
Solid Tumor
No
JIT-AB-106-G208
n/a
Molecular Targeted Therapy
ROS1
Lung Cancer (NSCLC)
No
JIT-20210023
n/a
Immunotherapy, Molecular Targeted Therapy
CDKN2A, MTAP
Solid Tumor
No
JIT-1403-0011 (Brightline-2)
BI 907828 is a so-called MDM2 inhibitor
Molecular Targeted Therapy
MDM2
Bile Duct Cancer (Cholangiocarcinoma), Lung Cancer (NSCLC), Pancreatic Cancer, Urothelial Cancer
No
24-20
BGB-24714 is a SMAC mimetic
Molecular Targeted Therapy
SMAC
Solid Tumor
No
24-16
SW-682 is a TEAD inhibitor
Small Molecule Inhibitor
TEAD
Mesothelioma, Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
Inactivating Alterations in TSC1 or TSC2
Solid Tumor
No
JIT-ENV-ONC-101
ENV- 101, a potent Hedgehog (Hh) pathway inhibitor
n/a
PTCH1 loss of function
Solid Tumor
No
JIT-20210023
n/a
Immunotherapy, Molecular Targeted Therapy
CDKN2A null, MTAP null
Solid Tumor
No
24-20
BGB-24714 is a SMAC mimetic
Molecular Targeted Therapy
Yes
Solid Tumor
No
24-16
SW-682 is a TEAD inhibitor
Small Molecule Inhibitor
NF2 or other Hippo pathway mutations
Mesothelioma, Solid Tumor
No
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy
KRASG12C
Solid Tumor
No
24-07
IAM1363 is a HER2 inhibitor
Molecular Targeted Therapy
Solid Tumor
No
24-05
BG-68501 is a CDK2 Inhibitor
Molecular Targeted Therapy
Solid Tumor
No
24-03
AMG 193 is a PRMT5 inhibitor
Molecular Targeted Therapy
Solid Tumor
No
23-30
Western Reserve vaccinia virus that expresses CCR2 and leptin-IL2.
Viral
Colorectal Cancer, Gastric/GEJ Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Skin Cancer/ Melanoma, Solid Tumor
No
23-29
REC-4881 is a MEK inhibitor
Molecular Targeted Therapy
Solid Tumor
No
23-28
AT-1965 is a CMTR2 inhibitor
Molecular Targeted Therapy
Not Required
Solid Tumor
No
23-24
FB849 is a HPK1 inhibitor
Immunotherapy
Not Required
Breast Cancer, Colorectal Cancer, Solid Tumor
No
23-23
BH3120 is a PD-L1 x 4-1BB Bispecific Monoclonal Antibody
Immunotherapy, Molecular Targeted Therapy
Solid Tumor
No
23-22
GSK4524101 is a POLQ inhibitor
Molecular Targeted Therapy
Not Required
Solid Tumor
Yes
23-19
RMC-9805 is a KRAS G12D inhibitor
Molecular Targeted Therapy
KRASG12D
Solid Tumor
No
23-18
LCB84 is an anti-TROP2 ADC
Antibody Drug Conjugate, Immunotherapy, Molecular Targeted Therapy
Anal Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
No
23-17
EGFR x HER3 bispecific antibody-drug conjugate
Antibody Drug Conjugate
Not Required
Lung Cancer (NSCLC), Solid Tumor
No
23-16
INCB099280 is a PD-L1 inhibitor. Adagrasib is a KRAS inhibitor (G12C).
Immunotherapy, Molecular Targeted Therapy
Not Required
Colorectal Cancer, Lung Cancer (NSCLC), Solid Tumor
No
23-15
HF158K1 is a HER2-targeting antibody liposome
Antibody Drug Conjugate
HER-2 positive or HER-2 low expression
Solid Tumor
No
23-10
ART6043 is a Polθ inhibitor
Molecular Targeted Therapy
*Genetic lesions known to cause loss of function of known DDR genes *Hormone-receptor status, breast cancer gene (BRCA) mutation
Solid Tumor
No
23-09
EO-3021 is an anti-CLDN18.2 antibody drug conjugate.
Antibody Drug Conjugate
CLDN18.2
Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
No
23-06
STX-478 is a PI3Kα small molecule inhibitor.
Molecular Targeted Therapy
PI3Kα
Breast Cancer, Solid Tumor
No
23-05
KT-253 is an MDM2 degrader
Molecular Targeted Therapy
Not Required
Lymphoma, Solid Tumor
Yes
23-02
TST003 is a GREM1 monoclonal antibody
Molecular Targeted Therapy
Solid Tumor
No
23-01
RO7623066 is a potent, selective small molecule inhibitor of USP1 that is being developed for the treatment of solid tumors.
Molecular Targeted Therapy
Monotherapy – Tumor Biopsy Cohort: have the following deleterious homologous recombination repair (HRR+) tumor mutations: BRCA1, BRCA2, PALB2, RAD51, RAD51B, RAD51C, RAD51D, BARD1, BRIP1, FANCA,...
Solid Tumor
No
22-39
JAB-2485 is a small molecule Aurora A inhibitor. Inhibition of Aurora A activity at the cellular level induces apoptosis and inhibits tumor growth.
Molecular Targeted Therapy
Not Required
Breast Cancer, Lung Cancer (SCLC), Solid Tumor
No
22-36
E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP...
Molecular Targeted Therapy
Not Required
Colorectal Cancer, Endometrial Cancer, Hepatocellular Cancer, Solid Tumor
No
22-35
MRT-2359 induces degradation of GSPT1 and associated downregulation of MYC transcription factors and their transcriptional outputs, which may lead to preferential anti-proliferative activity in MYC-driven...
Molecular Targeted Therapy
Not Required
Lung Cancer (NSCLC), Lung Cancer (SCLC), Lymphoma (Diffuse Large B-cell), Solid Tumor
No
22-23
ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling,...
Molecular Targeted Therapy, Small Molecule
Solid Tumor
No
22-20
PEEL-224 is a small molecule topoisomerase 1 (TOP1) inhibitor, which may lead to inhibiting the repair of single-strand DNA breaks, DNA replication, and tumor cell...
Molecular Targeted Therapy
Not Required
Solid Tumor
No
22-17
RMC-6236 inhibits the RAS(ON) state of multiple RAS variants both mutant and wild-type proteins.
Molecular Targeted Therapy
KRAS G12
Colorectal Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Solid Tumor
No
22-16
BP1001 a liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of...
Molecular Targeted Therapy
Not Required
Endometrial Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor
No
22-13
UCT-03-008, CDK4/6 inhibitor, inhibits protein kinase from working and therefore, potentially stopping cancer cells to grow. Protein kinases are enzymes that are involved in the...
Molecular Targeted Therapy, Small Molecule
Solid Tumor
No
22-09
CS5001 is a highly differentiated Antibody Drug Conjugate targeting ROR1. ROR1 is expressed across a variety of cancers, and may play an important role in...
Antibody Drug Conjugate, Molecular Targeted Therapy
Lymphoma, Solid Tumor
Yes
22-07
IMM2902 is a bispecific antibody designed to bind to and block CD47, a cell surface protein that inhibits the immune response, and also bind to...
Immunotherapy
CD47, ERBB2
Breast Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Solid Tumor
No
22-05
MT-6402 may bind and kill both tumor and immune PD-L1 expressing cells in a manner consistent with SLTA mediated cellular cytotoxicity through ribosomal inactivation, independent...
Immunotherapy
PD-L1
Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor
No
22-04
BAL0891 is a small-molecule inhibitor of TTK and PLK1 . Inhibition of both kinases may lead to disruption of the spindle assembly checkpoint (SAC) driving...
Immunotherapy (Targeted), Small Molecule
Not Required
Solid Tumor
No
22-02
IMP9064 is designed to inhibit the function of ATR, a component of the DNA damage repair system in all cells. Inhibition of DNA damage repair...
Molecular Targeted Therapy
PARP and ATR
Solid Tumor
No
21-41
ASP1570 is a small molecule immuno-oncology agent that is expected to act through the activation of immune cells in the tumor microenvironment.
Molecular Targeted Therapy
Not Required
Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Solid Tumor
No
21-29
GS-GS-1811 is a monoclonal antibody that is designed to bind to CCR8. It is thought to target Tumor-Infiltrating T Regulatory cells for depletion by enhancing...
Immunotherapy
Not Required
Breast Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor
No
21-25
BI 1810631 is an EGFR wild type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations including the HER2 YVMA insertion...
Molecular Targeted Therapy
Lung Cancer (NSCLC), Solid Tumor
Yes
20-26
Entrectinib: Inhibitor of the tyrosine kinases TrkA, TrkB, TrkC, ROS1, and ALK Alectinib: ALK kinase inhibitor
Antibody Drug Conjugate, Molecular Targeted Therapy, Small Molecule
Yes
Solid Tumor
No
20-08
TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway.
Immunotherapy, Molecular Targeted Therapy
Solid Tumor
No
18-26
MRTX849 is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).
Molecular Targeted Therapy
KRAS G12C
Solid Tumor
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000
